more

Axon Enterprise (AXON)

(Real Time Quote from BATS)

$426.36 USD

+0.52 (0.12%)

Updated Nov 4, 2024 09:30 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth D Momentum D VGM

Industry Rank:

Bottom 43% (143 out of 250)

Industry: Security and Safety Services

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Alnylam (ALNY) Reports Preliminary Onpattro Revenues for Q4

by Zacks Equity Research Published on January 08,2019

Alnylam (ALNY) reports preliminary revenues for Onpattro for the fourth quarter of 2018, and also provides other updates.

biotechs

FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101

by Zacks Equity Research Published on December 04,2018

The FDA accepts Novartis' (NVS) BLA for AVXS-101 and grants Priority Review to the same.

pharmaceuticals

Novartis Gets Approval for Gene Therapy Luxturna in Europe

by Zacks Equity Research Published on November 23,2018

Novartis (NVS) obtains EC approval for a one-time gene therapy, Luxturna for the treatment of patients with vision loss due to a genetic mutation in both copies of the RPE65gene.

pharmaceuticals

Dynavax (DVAX) Catches Eye: Stock Jumps 9.8%

by Zacks Equity Research Published on October 24,2018

Dynavax (DVAX) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

biotechs

Immunomedics (IMMU) Looks Good: Stock Adds 5.5% in Session

by Zacks Equity Research Published on October 22,2018

Immunomedics (IMMU) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Are Options Traders Betting on a Big Move in Axovant Sciences (AXON) Stock?

by Zacks Equity Research Published on October 11,2018

Investors need to pay close attention to Axovant Sciences (AXON) stock based on the movements in the options market lately.

AXONPositive Net Change

medical

Options Traders Expect Huge Moves in Axovant Sciences (AXON) Stock

by Zacks Equity Research Published on July 16,2018

Investors in Axovant Sciences (AXON) need to pay close attention to the stock based on moves in the options market lately.

AXONPositive Net Change

3 Gene Therapy Stocks Investors Can Bet on in Rest of 2018

by Ekta Bagri Published on July 12,2018

Gene therapy continues to be in focus with the recent spate of deals and acquisitions. We highlight three stocks, which have promising candidates in their pipeline.

Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More

by Zacks Equity Research Published on July 11,2018

Biogen's results from a phase II study in the much-pursued Alzheimer's disease was all over the biotech sector last week.

Axovant, Benitec Gain on Licensing Deal for Gene Therapy

by Zacks Equity Research Published on July 10,2018

Axovant Sciences' (AXON) shares gain, following the news of a licensing deal for oculopharyngeal muscular dystrophy candidate with Benitec Biopharma.

Solid (SLDB) Surges as FDA Lifts Clinical Hold on DMD Drug

by Zacks Equity Research Published on June 19,2018

Solid Biosciences' (SLDB) shares gained significantly after the FDA lifted the clinical hold on its phase I/II trial for its lead candidate, SGT-001 for DMD.